Here we show that TRAILv-KHYG-1 cells are modified NK cells engineered to express the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), which induces apoptosis in cancer cells upon binding to death receptors like DR5, a novel form of selectively inducing the DR5 pathway. Here, TNFRSF10B is linked to cancer.